Sera Prognostics Inc
SERA.OQ- Latest Trade
- trading higher1.75USD
- Change
- 0.45
- % Change
34.62%Positive
- Day Range
- 1.26 - 1.75
- 52-Week Range
- 1.17 - 15.50
As of Jun 26 2022. Values delayed up to 15 minutes
- Previous Close
- 1.30
- Open
- 1.28
- Volume
- 468,181.00
- 3 Month Average Trading Volume
- 2.36
- Shares Out (Mil)
- 30.93
- Market Cap
- 40.21
- Forward P/E
- -0.79
- Dividend Yield
- -99,999.99
Key Statistics
1.75 mean rating - 4 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 375.84
- Price To Book (Quarterly)
- 0.32
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.84
- Long Term Debt/Equity (Quarterly)
- 0.56
- Return On Investment (TTM)
- -43.71
- Return On Equity (TTM)
- -41.35
2021 (millions USD)
About Sera Prognostics Inc
Company Information
Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.
Address
2749 E. Parleys Way, Suite 200SALT LAKE CITY, UT
84109
United States
Industry
Business Services
Executive Leadership
- Gregory C. Critchfield
- Chairman of the Board, President, Chief Executive Officer
- Jay M. Moyes
- Chief Financial Officer
- Robert Gardner Harrison
- Chief Information Officer
- Jay Boniface
- Chief Scientific Officer
- Nadia F. Altomare
- Chief Commercial Officer
- Michael R. Foley
- Chief Medical Officer
- Jane F. Barlow
- Director
- Sandra A.J. Lawrence
- Director
- Evguenia Lindgardt
- Director
Markets Performance
Official Data PartnerCommodities
Future | Last | % Change |
---|---|---|
Gold | 1,825.70 | -- |
Copper | 693.65 | 0.33%Negative |
Brent Crude Oil | 113.12 | -- |
CBOT Soybeans | 1,609.00 | 0.99%Positive |
Stocks
Index | Last | % Change |
---|---|---|
S&P 500 | 3,911.74 | 3.06%Positive |
Euro STOXX 50 | 3,533.17 | 2.82%Positive |
FTSE 100 | 7,208.81 | 2.68%Positive |
Nikkei 225 | 26,491.97 | 1.23%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes